drugset

drugset / Trial / NCT01734512

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

NCT01734512 ↗

Phase 2 Completed 65 enrolled University of California, San Francisco Novartis Pharmaceuticals · collab Pacific Pediatric Neuro-Oncology Consortium · collab The Pediatric Low Grade Astrocytoma (PLGA) Foundation · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Timeline

Start: 2012-12-13
Primary completion: 2020-01-31
Completion: 2024-07-31

Publications

Haas-Kogan DA, Aboian MS, Minturn JE, Leary SES, Abdelbaki MS, Goldman S, Elster JD, Kraya A, Lueder MR, Ramakrishnan D, von Reppert M, Liu KX, Rokita JL, Resnick AC, Solomon DA, Phillips JJ, Prados M, Molinaro AM, Waszak SM, Mueller S. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. J Clin Oncol. 2024 Feb 1;42(4):441-451. doi: 10.1200/JCO.23.01838. Epub 2023 Nov 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	5 mg/m2	Oral

Indications